Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia
Shallis RM, Bewersdorf JP, Boddu PC, Zeidan AM. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert Review Of Anticancer Therapy 2019, 19: 717-729. PMID: 31422721, DOI: 10.1080/14737140.2019.1652095.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaHh pathway inhibitorsMyeloid leukemiaSurvival of AMLPathway inhibitorHh pathwayPoor-risk diseaseHedgehog pathway inhibitionStem cellsCombination therapyClinical trialsFirst approvalTherapeutic strategiesTherapeutic targetPathway inhibitionHematopoietic stem cellsNeoplasm therapyOlder populationTherapyHedgehog pathwayFurther studiesLeukemiaNormal hematopoiesisAdult stem cellsInhibitorsWhat are the most promising new agents in myelodysplastic syndromes?
Chandhok NS, Boddu PC, Gore SD, Prebet T. What are the most promising new agents in myelodysplastic syndromes? Current Opinion In Hematology 2019, 26: 77-87. PMID: 30632987, DOI: 10.1097/moh.0000000000000483.BooksConceptsMyelodysplastic syndromePromising new agentNew agentsAllogeneic hematopoietic stem cell transplantationManagement of MDSHigh-risk myelodysplastic syndromeHematopoietic stem cell transplantationRisk myelodysplastic syndromesLong-term remissionStem cell transplantationHigh-risk groupLow-risk groupGoal of therapyAcute myeloid leukemiaProgression of diseaseBone marrow failure syndromesGroup of disordersQuality of lifeMarrow failure syndromesTransfusion dependenceTherapeutic optionsTreatment optionsBcl-2 inhibitorsDisease prognosticationMyeloid leukemia